| Name | Title | Contact Details |
|---|
Acorn Technologies develops foundational building blocks for designing today`s advanced semiconductors and systems. With a special focus on wireless communications and mobile computing, the company offers a unique portfolio of patent-protected and licensable IP cores and scalable semiconductor process technologies that enable significantly better IC and system performance, processing power, speed and throughput. Acorn helps semiconductor manufacturers and chip design companies overcome technology bottlenecks to achieve their performance goals for advanced ICs used in next-generation devices. The company also serves the telecommunications system developer with IP cores, algorithms and other IP solutions for mobile, computing and wireless networking, helping them to address the demanding needs of an increasingly connected world.
DLT&V Systems Engineering Inc is a Phoenix, AZ-based company in the Computers and Electronics sector.
Metrospec Technology is a Saint Paul, MN-based company in the Computers and Electronics sector.
GreenPrint, a global environmental technology company, offers sustainability as a service with patent-protected programs that deliver environmental impact and bottom-line results. An Inc. 5000 company and a member of 1% Percent for the Planet, GreenPrint`s turnkey offerings help companies meet sustainability goals while increasing brand value and customer loyalty – making it easy for businesses to do well by doing good. GreenPrint, A Public Benefit Corporation, is on pace to offset over 30 million metric tons of carbon by 2025.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.